From counterculture to center-stage, alternative medical treatments, particularly psychedelics, have come a very long way in just a few years. It’s amazing to think that today, a research landmark like Johns Hopkins University is lending credence to the idea that psychedelic solutions are the future of medicine.

But that’s exactly what’s happening in what could be the most exciting recent development to happen in the field of mental health. At the Joseph V. Brady Behavioral Biology Research Center at Johns Hopkins, the psychedelic drug psilocybin has been used in experiments to treat depression.

The results are absolutely eye-opening, as Johns Hopkins treated 360 patients for their depression. The research found that their depression was, in many cases, lifted for months just from a treatment session or two.

Just as importantly, this is happening in a safe and controlled manner. This isn’t the “party drug” of past generations, where people would take drugs illegally in the pursuit of a good time. This time, it’s bona fide clinical pharmacology research that’s done in the name of potentially helping millions of patients suffering from mood disorders, anxiety, addiction, and more.

This is a boon to the community, but it’s also bringing attention and capital to clinics and companies focused on leveraging the power of psychedelic medical components like psilocybin and ketamine. Among the best-performing companies in this space are the ones that can develop and commercialize research-backed, psychedelic-based medical solutions.

The prime example of this today is a company called Champignon Brands (CSE: SHRM, OTC: SHRMF), which has a tradable stock and a leading psychedelic research clinic known as the Canadian Rapid Treatment Centre of Excellence, or CRTCE.

Champignon’s flagship clinic, located in Mississauga, Ontario, is fully operational and provides vast competitive advantages:

• 16 months of operating history
• It’s currently the only Health Canada-approved clinic to conduct randomized controlled trials (RCTs) for psilocybin
• Roughly $1,000,000 in revenue in the first full year of operations
• Over 1,500 ketamine treatments administered and over 300 patients serviced to date
• Colocated pharmacy with an agreement in place

A clinical center like this is massively de-risked because it is cash-flow positive. This methodology enables the company to bypass the CROs (contract research organizations), therefore accelerating timelines for commercialization.

That’s a huge relief for all the patients suffering from depression and who don’t want to take their old, ineffective, potentially addictive prescription medications. Champignon Brands and the CRTCE plan to more efficiently develop and bring novel treatments to the market for individuals struggling with depression, PTSD, and substance abuse disorders.

This way, Champignon can expand the company’s already considerable clinical footprint in the area of behavioral health. As capital flows in, the CRTCE seeks to establish new treatments and patents, along with pharmaceutical industry partnerships for ketamine and psilocybin.

Legal Notice:

This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

Never base any decision off of our emails. Wealth Research Group stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish.   Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Wealth Research Group LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign.  Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say. Please review our entire disclaimer at WealthResearchGroup.com/disclaimer.